The U.S. Navy demonstrated the manned-unmanned teaming capabilities of BQM-177s using Shield AI’s Hivemind software in a simulated CCA air combat ...

Anthropic’s agentic tool Claude Code has been an enormous hit with some software developers and hobbyists, and now the ...

Concepts NREC introduces Agile Engineering Design System v2025.2 with advanced volute modeling, secondary flow capabilities ...

Anthropic is bringing Claude for healthcare, following a similar move by OpenAI for ChatGPT. In a blog post , Anthropic explained that Claude is expanding into Healthcare, and it's testing new ...

Lumus showed me a fragile prototype that delivered a surprisingly wide, clean view, hinting at the future of smart glasses.

Dec 12 (Reuters) - Arcus Biosciences (RCUS.N), opens new tab said on Friday it would stop a late-stage study testing its experimental cancer drug combination in patients with advanced stomach and ...

A key late-stage trial of Arcus Biosciences and Gilead Sciences' anti-TIGIT antibody domvanalimab has flopped, leading Arcus to refocus its R&D priorities and abandon several studies of the drug. The ...

Arcus Biosciences said it will discontinue a late-stage trial for its potential cancer treatment due to futility. The study, which was being conducted in partnership with Gilead Sciences, aimed to ...

GameSpot may get a commission from retail offers. The game puts players in the role of Hugh, an astronaut in the near future who is accompanied by Diana, an android who appears as a little girl. The ...

The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futility Arcus is continuing to expand its development program for ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

Arcus Biosciences Inc (RCUS) stock reached a significant milestone, hitting a 52-week high of 26.32 USD, representing a remarkable 304% increase from its 52-week low of 6.50 USD. According to ...